Comparison

Sotrastaurin (AEB071) European Partner

Item no. S2791-5
Manufacturer Selleckchem
CASRN 425637-18-9
Amount 5 mg
Quantity options 1 g 10 g 10 mM/1 mL 25 mg 5 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias PKCalpha,PKCbeta,PKCdelta,PKCepsilon,PKCeta,PKCtheta,PKC
Similar products Sotrastaurin
Available
Storage Conditions
2 years -80 in solvent
Molecular Weight
438, 48
Administration
Orally administrated
Animal Models
male Wistar/F rats
Clinical Trials
Sotrastaurin has finished Phase II clinical trial in patients with Kidney Transplantation.
Dosages
10 mg/kg and 30 mg/kg
Formulation
Saline
IC50
0.95 nM (Ki), 0.95 nM (Ki), 0.95 nM (Ki), 0.95 nM (Ki), 0.95 nM (Ki), 0.95 nM (Ki)
In vitro
Sotrastaurin (< 10uM) treatment effectively abrogated at low nanomolar concentration markers of early T-cell activation, such as interleukin-2 secretion and CD25 expression, in primary human and mouse T cells. Sotrastaurin (200 nM) inhibits the CD3/CD28 antibody- and alloantigen-induced T-cell proliferation responses in the absence of nonspecific antiproliferative effects. Sotrastaurin (<3 uM) markedly inhibits lymphocyte function-associated antigen-1-mediated T-cell adhesion. [1] Sotrastaurin(< 20 uM) selectively impair the proliferation of CD79 mutant ABC DLBCL cell lines, correlating with decreased NF-kappaB signaling avctivity. AEB071 at concentration of 5 uM induces G1 arrest and/or cell death in CD79 mutant cells. [2]
In vivo
Sotrastaurin (80 mg/kg) results in significant inhibition of in vivo tumor growth in a subcutaneous TMD8 xenograft model in SCID. [2] Sotrastaurin orally administrated at 10 mg/kg and 30 mg/kg b.i.d. show a dose-dependent immunosuppressive effect leading to pronounced prolongation of heart allograft survival in rats. [3]
Kinase Assay
Protein Kinase Assays, Classical and novel PKC isotypes are assayed by scintillation proximity assay technology. In brief, the assay is performed in 20 mM Tris-HCl buffer, pH 7.4, and 0.1% bovine serum albumin by incubating 1.5 uM of the peptide substrate with 10 uM [33P]ATP, 10 mM Mg (NO3)2, 0.2 mM CaCl2, and PKC at a protein concentration varying from 25 to 400 ng/mL, and lipid vesicles containing 30 mol% phosphatidylserine, 5 mol% diacylglycerol (DAG), and 65 mol% phosphatidylcholine at a final lipid concentration of 0.5 uM. Incubation is performed for 60 min at room temperature. The reaction is stopped by adding 50 ul of a mixture containing 100 mM EDTA, 200 uM ATP, 0.1% Triton X-100, and 0.375 ug/well streptavidin-coated scintillation proximity assay beads in PBS without Ca2+ and Mg2+. Incorporated radioactivity is measured in a MicroBetaTrilux counter for 1 min.
Solubility (25C)
DMSO 87 mg/mL, Water <1 mg/mL, Ethanol 2 mg/mL
Information
Sotrastaurin (AEB071) is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM in a cell-free assay; inactive to PKCζ. Phase 2.
Chemical Name
3-(1H-indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4-yl)-1H-pyrrole-2, 5-dione
Features
Unlike former PKC inhibitors, Sotrastaurin does not enhance apoptosis of murine T-cell blasts in a model of activation-induced cell death.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?